Navigation Links
PAREXEL Reports Second Quarter Fiscal Year 2009 Financial Results
Date:1/26/2009

Company anticipates reporting consolidated service revenue in the range of $273 to $283 million and earnings per diluted share in the range of $0.23 to $0.25. On a GAAP basis, for Fiscal Year 2009, consolidated service revenue is expected to be in the range of $1.095 to $1.115 billion, and earnings per diluted share to be in the range of $0.80 to $0.84 (previously issued revenue guidance was service revenue of $1.080 to $1.110 billion, and diluted earnings per share of $0.75 to $0.82). Excluding the impact of the second quarter contract termination as previously described, the Company expects to achieve diluted earnings per share of $0.94 to $0.98 for Fiscal Year 2009. For Calendar Year 2009, consolidated service revenue is expected to be in the range of $1.135 to $1.175 billion, and earnings per diluted share are projected to be in the range of $0.96 to $1.04.

In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), the Company uses certain non-GAAP financial measures. The Company believes that presenting the non-GAAP financial measures contained in this press release assists investors and others in gaining a better understanding of its core operating results and future prospects, especially when comparing such results to previous periods or forecasted guidance, because such measures exclude items that are outside of the Company's normal operations and/or, in certain cases, are difficult to forecast accurately for future periods. Management uses non-GAAP financial measures, in addition to the measures prepared in accordance with GAAP, as the basis for measuring the Company's core operating performance and comparing such performance to that of prior periods and to the performance of its competitors for the same reasons stated above. Such measures are also used by management in its financial and operating decision-making. Non-GAAP financial measures are not meant to be considered supe
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine news :

1. PAREXEL Announces Date of Second Quarter Fiscal Year 2009 Earnings Release and Conference Call
2. PAREXEL Reports Preliminary Second Quarter Results
3. PAREXEL International to Present at NASDAQ OMX 22nd Investor Program
4. PAREXEL Reports First Quarter Fiscal Year 2009 Financial Results
5. PAREXEL International to Present at Robert W. Bairds 2008 Growth Stock Conference
6. PAREXEL International to Present at Bank of America 2008 Smid Cap Conference
7. Matrixx Initiatives, Inc. Reports Third-Quarter Net Sales Increased 26% to $38.7 Million, Net Income Increased to $4.8 Million, or $0.50 Earnings Per Share
8. Quest Diagnostics Reports Growth in Revenue and Earnings for Fourth Quarter 2008 and Provides 2009 Guidance
9. Wyeth Reports Earnings Results for the 2008 Full Year and Fourth Quarter
10. MedPredict Publishes Two New Reports Providing Expert Analysis of Malignant Hematology Drug Development
11. Thomson Reuters Publishes Three Pharma Matters Reports Covering the Third Quarter of 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... By Serena Gordon ... -- A new type of sensor for people with ... body using saliva instead of blood, researchers report. Scientists ... successfully tested it using artificial saliva. It uses light, metal ... blood sugar. "Everybody knows that diabetics have to prick ...
(Date:7/13/2014)... Recently, 2014QuinceaneraDresses.com, the distinguished special occasion dress manufacturer ... gorgeous Quinceanera dresses . , In ... outfits is huge. Therefore, 2014QuinceaneraDresses.com is striving to ... released dresses are made according to the latest ... , It is worthy of mention that ...
(Date:7/13/2014)... 13, 2014 Epidemiologists forecast an increase ... 6MM, from 8,062 diagnosed incident cases in 2013 to ... Growth Rate (AGR) of 4.35%, during the forecast period. ... of diagnosed incident cases of aGVHD in the 6MM, ... the lowest number of diagnosed incident cases of aGVHD, ...
(Date:7/13/2014)... 13, 2014 Wright & Schulte LLC ... been scheduled in July of 2015, in U.S. District ... are in the discovery process in the South ... is presiding over the multidistrict litigation (MDL). The complaints ... of individuals who allege that they took the statin ...
(Date:7/13/2014)... 2014 Hope Palliative & Hospice Care announced ... group at the Tamarack Senior Living Community in Palatine, IL. ... A.M. on the 3rd Wednesdays of every month. This ... Tamarack Community located at 55 S. Greeley St. Palatine, IL ... there is no cost for the group. , “A ...
Breaking Medicine News(10 mins):Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 2Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 3Health News:2014QuinceaneraDresses.com Releases Its New Quinceanera Dresses 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 3Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 4Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 2Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 3Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 4Health News:Hope Hospice Announces Grief Support Group at the Tamarack Senior Living Community 2
... drug to the usual three-drug HIV treatment regimen is not ... the HIV load// or the drug resistance, the new study ... JAMA, a theme issue on HIV/AIDS. ,Roy M. ... New York, presented the findings of the study today at ...
... used HIV treatments, researchers found one triple-drug therapy was ... the blood when used as a first-line treatment. Results ... among three different therapies the optimal approach for patients ... reported at the XVI International AIDS Conference (AIDS 2006). ...
... new study published in the September 15, 2006 issue ... Society, says that African-Americans are least likely to// ask ... says that the level of interest displayed by Caucasian ... This fact may lead to the African-Americans making less-informed ...
... has said that better quality drugs and child medication ... ,Speaking to Agence France-Presse (AFP) ... in Toronto he said, "We definitely need to improve ... talking to pharmaceuticals. We definitely want to buy second-line ...
... radical changes in business with tangible growth in Asian countries, ... of a jet setting pace, so much a part of ... a demographic crisis, with a rampant spread of mental health ... palpable, and is attributed to the high stress in the ...
... in on a weakened scout cell, which is known to ... out that cancer in some of the transplant patients shows ... for the immune system. Researchers are optimistic that by ... find ways to prevent the onset of cancer. The reason ...
Cached Medicine News:Health News:Four-Drug AIDS Treatment Regimen Deemed Of No Use 2Health News:Study Compares First-Line Drug Therapies For Treating HIV 2Health News:Study Compares First-Line Drug Therapies For Treating HIV 3Health News:Study Compares First-Line Drug Therapies For Treating HIV 4Health News:African-Americans Pose Less Questions To Treating Doctors 2Health News:Need for Newer AIDS Drugs In China 2
(Date:7/11/2014)... -- Research and Markets  has announced the addition ... report to their offering. ... hollow needle commonly used with a syringe to inject ... from it. A hypodermic needle is used for rapid ... be ingested. Hypodermic needles are broadly classified into non-safety ...
(Date:7/11/2014)... , July 11, 2014 ... at 4,396.20, down 0.52%, the Dow Jones Industrial Average finished ... closed at 1,964.68, down 0.41%. The losses were broad based ... negative. The S&P 500 Health Care Sector Index ended the ... 2.75% in the last one month. Investor-Edge has initiated coverage ...
(Date:7/11/2014)... , July 11, 2014  Veran Medical ... announced today the positive, cost-effective final results ... SPiNPerc™ procedure. The SPiNPerc endobronchial percutaneous biopsy ... percutaneous approach to biopsy when a traditional ... and physicians experience positive financial outcomes when ...
Breaking Medicine Technology:Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4Veran Medical Publishes Lung Cancer Patient Management Study 2
... 4, 2011 Reportlinker.com announces that a new ... European Market for Cardiac Rhythm ... http://www.reportlinker.com/p0488652/European-Market-for-Cardiac-Rhythm-Management-Electrophysiology--Ablation-Devices-2011.html European Market ... 2011 (15 countries) In 2010, ...
... 2011 Reportlinker.com announces that a ... in its catalogue: ... – Bone Grafting and Hyaluronic Acid ... http://www.reportlinker.com/p0488653/European-Markets-for-Orthopedic-Biomaterials-2011-–-Bone-Grafting-and-Hyaluronic-Acid-Viscosupplementation-15-Countries.html The ...
Cached Medicine Technology:Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 2Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 3Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 4Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 5Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 6Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 7Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 8Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 9Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 10Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 11Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 12Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 13Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 14Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 15Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 16Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 17Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 18Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 19Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 20Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 21Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 2Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 3Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 4Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 5Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 6Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 7Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 8Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 9Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 10Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 11Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 12Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 13Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 14Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 15Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries) 16
Smaller diameter wire probes & olive shape tips provide easier insertion through the lacrimal sac, 35cm (14 in) long, ID- .30mm (.012in); OD- .64mm (.025 in). S.S. Probes: .40mm x 11cm (27 G x 4 1/4...
...
Pre-set guard for precise depth incision, bi-directional blade can cut left or right. 250 micron....
Universal, clear, lightweight plastic with smooth edges & ventilation holes for patient comfort...
Medicine Products: